Video

Q&A With Mark Freedman, MD, of Ottawa Hospital: Study Results show Benefits of Teriflunomide in Multiple Sclerosis Treatment

Author(s):

As a treatment for multiple sclerosis teriflunomide has shown benefits over a long development period and has proven effective in the treatment of patients with the relapsing-remitting form of the condition.

As a treatment for multiple sclerosis teriflunomide has shown benefits over a long development period and has proven effective in the treatment of patients with the relapsing-remitting form of the condition.

Mark Freedman, MD, FAAN, from Ottawa Hospital discussed how the medication works and what its safety profile is during the American Academy of Neurology Annual Meeting in Washington DC. The medication is indicated for reducing relapses, slowing disability and reducing MRI activity after being in development for more than a decade.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.